Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies: Systematic Review and Meta-analysis -

Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivascular Endothelial Growth Factor Monoclonal Antibodies: Systematic Review and Meta-analysis
Information type: Systematic reviews
Source: JAMA Opthalmology
Specialities: Eyes and vision
Summary
This analysis of 21 RCTs of intravitreal ranibizumab (R) and/or bevacizumab (B) in the treatment of ophthalmological conditions found no increase in risk of major CV events or nonocular haemorrhagic events; B was however associated with an increased risk of VTE compared to R.
UKMi comment
The studies and the meta-analyses were not powered to correctly assess these risks, and more safety data are required.
Related links: